Authors

Latest:

Dr Kesireddy on the Future Use of Capivasertib Plus Fulvestrant in HR+/HER2– Breast Cancer

Meghana Kesireddy, MBBS, discusses the pending FDA approval of the AKT inhibitor capivasertib plus the selective estrogen receptor degrader fulvestrant in patients with hormone receptor–positive, HER2-negative breast cancer.

Mojun Zhu, MD

Latest:

Dr. Zhu on Key Results From the TOPAZ-1 Trial in Biliary Tract Cancer

Mojun Zhu, MD, discusses key findings from the phase 3 TOPAZ-1 trial in patients with biliary tract cancer.

Erminia Massarelli, MD, PhD, MS

Latest:

Dr Massarelli on Using Selpercatinib and Pralsetinib in Treating Advanced Non-Small Cell Lung Cancer

Erminia Massarelli, MD, PhD, MS, discusses selpercatinib and pralsetinib in treating advanced non-small cell lung cancer.

Neel P. Chudgar, MD

Latest:

Dr Chudgar on Defining Resectability in NSCLC

Neel P. Chudgar, MD, discusses his presentation on resectability in non–small cell lung cancer at the 21st Annual Winter Lung Cancer Conference®.

Gautam Jha, MD

Latest:

Dr Jha on Community Accrual to the ECLIPSE Trial in Prostate Cancer

Gautam Jha, MD, discusses collaborative efforts between community and academic oncologists to accrue patients to the ECLIPSE trial.

Tomer Mark, MD

Latest:

Dr. Mark on Questions Regarding Sequencing in Multiple Myeloma

Tomer Mark, MD, discusses making sequencing decisions amid the array of available treatment options in multiple myeloma.

David Gerber, MD

Latest:

How are Antibody-Drug Conjugates Shaping the NSCLC Treatment Paradigm? With David Gerber, MD

Dr Gerber discusses the evolving role of ADCs in NSCLC, focusing on findings from clinical trials and considerations regarding the toxicity profile of TROP2-directed ADCs.

Puja S. Venkat

Latest:

Dr. Venkat on Unmet Needs in Ovarian Cancer

Puja S. Venkat, MD, discusses unmet needs in ovarian cancer.

Yasir Y. Elamin, MD

Latest:

BRIGHTSTAR: Local Consolidative Therapy with Brigatinib in Tyrosine Kinase Inhibitor-Naïve ALK-Rearranged Metastatic NSCLC

Expert oncologist Yasir Elamin, MD, shares data from the BRIGHTSTAR trial and considers how it may inform real-world use of brigatinib in patient with ALK-rearranged metastatic non–small cell lung cancer.

Bilal A. Siddiqui, MD

Latest:

Dr. Siddiqui on Defining Characteristics of Nonmetastatic CRPC

Bilal A. Siddiqui, MD, discusses the nuances of defining the characteristics of nonmetastatic castration-resistant prostate cancer.

Amitkumar Mehta, MD, O'Neal Comprehensive Cancer Center at UAB

Latest:

Evolving Therapies in R/R DLBCL: Concluding Remarks

Nitya Raj, MD,

Latest:

Dr. Raj on Injection Site Pain With Octreotide Long-Acting Release Vs Lanreotide in NETs

Nitya Raj, MD, discusses the results of a phase 4 trial comparing injection site pain with octreotide long-acting release vs lanreotide in well-differentiated neuroendocrine tumors.

Greg Nowakowski, MD, Mayo Clinic

Latest:

Dr Nowakowski on Monitoring Epcoritamab-Associated ICANS and CRS in Follicular Lymphoma

Grzegorz S. Nowakowski, MD, discusses toxicity monitoring strategies for epcoritamab treatment in relapsed/refractory follicular lymphoma.

Dario R. Roque, MD

Latest:

Dr. Roque on the Importance of Biomarker Testing in Advanced Endometrial Cancer

Dario R. Roque, MD, discusses how biomarker testing can lead to more accurate and effective treatment selection in advanced endometrial cancer.

Stephanie E. Weiss, MD, FASTRO

Latest:

Dr. Weiss on Selecting Optimal Radiation Therapy for Brain Metastases

Stephanie E. Weiss, MD, FASTRO, discusses selecting optimal radiation therapy for patients with brain metastases.

Marilyn Huang, MD, MS

Latest:

Dr Huang on the Use of Neoadjuvant PARP Inhibitors in Advanced Ovarian Cancer

Marilyn Huang, MD, discusses the need for non-chemotherapy options in advanced ovarian cancer, as well as data on the use of neoadjuvant PARP inhibitors for this population in the phase 1 NOW study.

Iman Imanirad, MD

Latest:

Dr Imanirad on Toxicity Management for Encorafenib Plus Cetuximab in BRAF-Mutant mCRC

Iman Imanirad, MD, medical oncologist, gastrointestinal oncology, Moffitt Cancer Center, discusses the management of toxicities associated with standard-of-care encorafenib plus cetuximab for patients with previously treated microsatellite stable BRAF V600E metastatic colorectal cancer.

Brandon Mahal, MD

Latest:

Dr. Mahal on the Emerging Role of Epigenomics in Prostate Cancer

Brandon Mahal, MD, discusses the emerging role of epigenomics in prostate cancer.

Bruce Feinberg, DO

Latest:

The COVID-19 Pandemic Will Have Long-Term Impact on Oncology Practices

The COVID-19 pandemic created new patient care challenges in oncology, such as how to reduce risks of virus exposure for patients who may be immunocompromised and switching from in-person visits to telemedicine.

Pooja Advani, MBBS, MD

Latest:

Dr Advani on the Evaluation of Ribociclib/Endocrine Therapy in HR+/HER2– Breast Cancer

Pooja Advani, MBBS, MD, discusses the use of ribociclib plus endocrine therapy for patients with hormone receptor–positive, HER2– breast cancer.